Spots Global Cancer Trial Database for Treatment of Relapsed Low-Grade or Follicular Lymphoma With Rituximab (Also Known as Rituxan, IDEC-C2B8, IDEC-102)
The following info and data is provided "as is" to help patients around the globe.
We do not endorse or review these studies in any way.
Trial Identification
Brief Title: Treatment of Relapsed Low-Grade or Follicular Lymphoma With Rituximab (Also Known as Rituxan, IDEC-C2B8, IDEC-102)
Official Title: Pivotal Phase III Multi-Center Study to Evaluate the Safety and Efficacy of Once Weekly Times Four Dosing of IDEC-C2B8 (IDEC-102) in Patients With Relapsed Low-Grade or Follicular B-Cell Lymphoma
Study ID: NCT00168740
Interventions
Study Description
Brief Summary: Rituximab is an antibody made in a laboratory. It binds to lymphoma cells and kills them. Treatment of recurrent B-cell lymphoma with rituximab may delay or prevent relapses. A total of 166 patients with recurrent B-cell lymphoma were given intravenous rituximab once a week for 4 weeks. The patients' tumors were measured before and after treatment. Ten patients had a complete response and 70 patients had a partial response to rituximab. The median duration of response was 11.2 months.
Detailed Description:
Eligibility
Minimum Age: 18 Years
Eligible Ages: ADULT, OLDER_ADULT
Sex: ALL
Healthy Volunteers: No
Locations
University of Arkansas for Medical Sciences, Little Rock, Arkansas, United States
City of Hope Natioal Medical Center, Duarte, California, United States
Scripps Memorial Hospital, La Jolla, California, United States
UCSD Stem Cell Laboratory, La Jolla, California, United States
Hoag Hospital, Newport Beach, California, United States
Sutter Cancer Center, Sacramento, California, United States
Sidney Kimmel Cancer Center, San Diego, California, United States
University of California, San Francisco, San Francisco, California, United States
Stanford University Medical Center, Stanford, California, United States
Kaiser Permanente Medical Center, Vallejo, California, United States
Rocky Mountain Cancer Center, Denver, Colorado, United States
Georgetown University Medical Center, Washington, District of Columbia, United States
Robert H. Lurie Cancer Center, Northwestern University, Chicago, Illinois, United States
University of Iowa General Hospital, Iowa City, Iowa, United States
University of Kentucky Medical Center, Lexington, Kentucky, United States
Louisiana State University, Shreveport, Louisiana, United States
University of Maryland Cancer Center, Baltimore, Maryland, United States
Michigan State University, East Lansing, Michigan, United States
St. Louis University Medical Center, St. Louis, Missouri, United States
Roswell Park Cancer Center, Buffalo, New York, United States
University of Rochester Cancer Center, Rochester, New York, United States
Fox Chase Cancer Center, Philadelphia, Pennsylvania, United States
University of Pittsburgh Medical Center, Pittsburgh, Pennsylvania, United States
The West Clinic, P.C., Memphis, Tennessee, United States
Texas Oncology, P.A., Dallas, Texas, United States
M.D. Anderson Cancer Center, Houston, Texas, United States
University of Texas Health Sciences Center, San Antonio, Texas, United States
University of Virginia, Charlottesville, Virginia, United States
Fred Hutchinson Cancer Research Center, Seattle, Washington, United States
Ottawa General Hospital, Ottawa, Ontario, Canada
Toronto-Sunnybrook Regional Cancer Center, Toronto, Ontario, Canada
Contact Details
Name: Antonio J. Grillo-Lopez, M.D.
Affiliation: Biogen
Role: STUDY_DIRECTOR
Take Control of Your Skin and Body Changes Today.
Try out Spots for free, set up only takes 2 mins.
Join others from around the world:
